Huntington National Bank’s Cocrystal Pharma COCP Stock Holding History

Huntington National Bank’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-69	Closed	–	–	2066
2022 Q2	$0	Buy	+69	New	+$368	﹤0.01%	2094

Other funds holding COCP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Huntington National Bank's COCP Position: Q3 2022 in Review

Huntington National Bank sold out of Cocrystal Pharma (COCP) in Q3 2022, closing a stake of 69 shares.

Huntington National Bank first reported a position in COCP in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 27 funds tracked by Wall St. Rank hold COCP as of Q3 2022.

Huntington National Bank reported no remaining Cocrystal Pharma position as of Q3 2022 after selling out during the quarter.
Huntington National Bank sold 69 Cocrystal Pharma shares in Q3 2022.
Huntington National Bank first reported a position in Cocrystal Pharma in Q2 2022 and held it in 1 quarter.
Huntington National Bank's Cocrystal Pharma position peaked at $0 in Q2 2022.
27 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q3 2022.

Based on Huntington National Bank's 13F filing for Q3 2022, filed 7 Nov 2022.